CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Provide Feedback on Draft Recommendations
Initial Recommendation Issued: April 1, 2021
Feedback Deadline: April 16, 2021
Feedback Template: Stakeholder Feedback on a pERC Initial Recommendation
| Project Number | PC0230-000 |
|---|---|
| Brand Name | Alunbrig |
| Generic Name | Brigatinib |
| Tumour Type | Lung |
| Indication | Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer |
| Funding Request | For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor. |
| Review Status | Open for Feedback on Recommendation |
| Pre Noc Submission | Yes |
| NOC Date | March 3, 2021 |
| Manufacturer | Takeda Canada Inc. |
| Sponsor | Takeda Canada Inc. |
| Submission Date | September 30, 2020 |
| Submission Deemed Complete | October 15, 2020 |
| Submission Type | Initial |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | October 15, 2020 |
| Check-point meeting | December 16, 2020 |
| pERC Meeting | March 18, 2021 |
| Initial Recommendation Issued | April 1, 2021 |
| Feedback Deadline ‡ | April 16, 2021 |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued | |
| Therapeutic Area | (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
